Zydus Cadila receives tentative approval from USFDA for Osimertinib Tablets

Zydus Cadila has received tentative approval from the USFDA to market Osimertinib Tablets in the strengths of 40 mg and 80 mg (US RLD: Tagrisso Tablets). Osimertinib is used to treat lung cancer. It belongs to a class of drugs known as kinase inhibitors. Osimertinib works by slowing or stopping the growth of cancer cells. It binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors.

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.627.7 as compared to the previous close of Rs. 619.35. The total number of shares traded during the day was 320001 in over 6324 trades.

The stock hit an intraday high of Rs. 635.15 and intraday low of 617. The net turnover during the day was Rs. 201040753.

Source : Equity Bulls

Keywords